Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45:511–20.

Article  PubMed  PubMed Central  Google Scholar 

Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review. BMC Med. 2016;14:191. https://doi.org/10.1186/s12916-016-0735-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6:237–48.

Article  PubMed  Google Scholar 

Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399:259–69.

Article  CAS  PubMed  Google Scholar 

Therapeutic Repurposing-National Center for Advancing Translational Sciences (NCATS) [cited 2022 May 10]. Available at: https://sites.google.com/ncats.nih.gov/therapeutic-repurposing/home.

CURE Drug Repurposing Collaboratory | Critical Path Institute [cited 2022 May 10]. Available at: https://c-path.org/programs/cdrc/.

Begley CG, Ashton M, Baell J, Bettess M, Brown MP, Carter B, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci Transl Med. 2021;13:e5524.

Article  Google Scholar 

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.

Article  CAS  PubMed  Google Scholar 

FDA Briefing Information for the February 22, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2012 [cited 2021 Jan 17]. Available at: https://wayback.archive-it.org/7993/20170404152021/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm292314.htm.

Khorassani FE, Misher A, Garris S. Past and present of antiobesity agents: focus on monoamine modulators. Am J Health Syst Pharm. 2015;72:697–706.

Article  CAS  PubMed  Google Scholar 

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. United States; 2020. p. 1–8.

Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299–307.

Article  PubMed  PubMed Central  Google Scholar 

US FDA. Qsymia Prescribing Information (version 2012). 2012 [cited 2021 Jan 17]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf.

US FDA. Qsymia Approval Letter. 2012 [cited 2021 Jan 17]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022580Origs000ltr.pdf.

US FDA. Qsymia-Risk Evaluation and Mitigation Strategy (REMS). 2017 [cited 2021 Jan 17]. Available AT: https://www.accessdata.fda.gov/drugsatfda_docs/rems/Qysmia_2017-07-03_REMS_full.pdf.

US FDA. Topiramate (Topamax) Prescribing Information (October 2012). 2012 [cited 2021 Dec 5]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020505s050lbl.pdf.

US FDA. REMS Assessment: Planning and Reporting Guidance for Industry. Silver Spring: US FDA; 2019. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-assessment-planning-and-reporting.

Khan NF, Bykov K, Glynn RJ, Barnett ML, Gagne JJ. Coprescription of opioids with other medications and risk of opioid overdose. Clin Pharmacol Ther. 2021;110:1011–7.

Article  CAS  PubMed  Google Scholar 

Center for Medicare and Medicaid Service: Chronic Conditions Data Warehouse. CCW Condition Algorithms. 2019. Available at: https://www2.ccwdata.org/web/guest/condition-categories.

Sarayani A, Albogami Y, Elkhider M, Hincapie-Castillo JM, Brumback BA, Winterstein AG. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. BMJ Qual Saf. 2020;29:636–44.

Article  PubMed  Google Scholar 

Chen C-Y, Bussing R, Hartzema AG, Shuster JJ, Segal R, Winterstein AG. Stimulant use following the publicity of cardiovascular safety and the introduction of patient medication guides. Pharmacoepidemiol Drug Saf. 2016;25:678–86.

Article  CAS  PubMed  Google Scholar 

Hurt RT, Edakkanambeth Varayil J, Mundi MS, Martindale RG, Ebbert JO. Designation of obesity as a disease: lessons learned from alcohol and tobacco. Curr Gastroenterol Rep. 2014;16:415.

Article  PubMed  Google Scholar 

Albogami Y, Wei Y-JJ, Winterstein AG. Generalizability and accuracy of IBM MarketScan health risk assessment instrument data for augmentation of commercial claims data. Pharmacoepidemiol Drug Saf. 2022;31:100–4.

Article  PubMed  Google Scholar 

Centers for Disease Control and Prevention. Adult obesity prevalence maps—May 2022 Update [cited 2022 Feb 9]. Available at: https://www.cdc.gov/obesity/data/prevalence-maps.html#overall.

Sari C, Seip RL, Umashanker D. Case report: off label utilization of topiramate and metformin in patients with BMI ≥50 kg/m2 prior to bariatric surgery. Front Endocrinol. 2021;12:588016.

Article  Google Scholar 

Sarayani A, Albogami Y, Winterstein AG. Effectiveness of risk evaluation and mitigation strategies to prevent maternal exposure to a Topiramate weight loss product. Pharmacoepidemiol Drug Saf. 2019;28:245–6.

Albogami Y, Sarayani A, Hincapie-Castillo JM, Winterstein AG. Real-world fetal exposure to acne treatments in the United States: a retrospective analysis from 2006 to 2015. Drug Saf. 2021;44:447–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarayani A, Albogami Y, Thai TN, Smolinski NE, Patel P, Wang Y, et al. Prenatal exposure to teratogenic medications in the era of risk evaluation and mitigation strategies. Am J Obstet Gynecol. 2022;227:263.e1-263.e38.

Article  CAS  Google Scholar 

Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes. 2018;42:495–500.

Article  CAS  Google Scholar 

Ammann EM, Kalsekar I, Yoo A, Johnston SS. Validation of body mass index (BMI)-related ICD-9-CM and ICD-10-CM administrative diagnosis codes recorded in US claims data. Pharmacoepidemiol Drug Saf. 2018;27:1092–100.

Article  PubMed  Google Scholar 

Samadoulougou S, Idzerda L, Dault R, Lebel A, Cloutier A, Vanasse A. Validated methods for identifying individuals with obesity in health care administrative databases: a systematic review. Obes Sci Pract. 2020;6:677–93.

Article  PubMed  PubMed Central  Google Scholar